We enjoyed a strong first half of the year! During the second quarter, our momentum continued, as we advanced our mission of working together to deliver favorable commercial and clinical development results. During the quarter we remained dedicated to advancing our mission of working together...

Our approved brands remain a key driver of performance, while expanded international partnerships and steady advancement in our clinical development programs further strengthen our position. We are also evaluating select acquisition opportunities that align with our strategic objectives. As we look ahead, we remain committed...

Cumberland’s business strategy has been to acquire and commercialize a portfolio of branded pharmaceuticals that we can grow through our dedicated sales organization domestically and through our partners internationally. We’ve also built an internal development capability, which enables us to develop and register new medicines,...